Recombinant Human MTOR 293 Cell Lysate

• Cat.No.: MTOR-4068HCL

Specification

• Description: Antigen standard for mechanistic target of rapamycin (serine/threonine kinase) (MTOR) is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.
• Source: HEK 293 cells
• Species: Human
• Components: This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).
• Size: 0.1 mg
• Storage Instruction: Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.
• Applications: ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.
• Tag: Non

Gene Information

• Gene Name: MTOR mechanistic target of rapamycin (serine/threonine kinase) [ Homo sapiens ]
• Official Symbol: MTOR
• Synonyms: MTOR; mechanistic target of rapamycin (serine/threonine kinase); FK506 binding protein 12 rapamycin associated protein 1 , FRAP, FRAP1, FRAP2; serine/threonine-protein kinase mTOR; dJ576K7.1 (FK506 binding protein 12 rapamycin associated protein 1); FK506 binding protein 12 rapamycin associated protein 2; FKBP rapamycin associated protein; FKBP12 rapamycin complex associated protein 1; FLJ44809; mammalian target of rapamycin; RAFT1; rapamycin and FKBP12 target 1; rapamycin associated protein FRAP2; rapamycin target protein; RAPT1; rapamycin target protein 1; FKBP-rapamycin associated protein; FKBP12-rapamycin complex-associated protein 1; FK506 binding protein 12-rapamycin associated protein 1; FK506 binding protein 12-rapamycin associated protein 2; FK506-binding protein 12-rapamycin complex-associated protein 1; FRAP; FRAP1; FRAP2
• Gene ID: 2475
• mRNA Refseq: NM_004958
• Protein Refseq: NP_004949
• MIM: 601231
• UniProt ID: P42345
• Chromosome Location: 1p36
• Pathway: AMPK signaling, organism-specific biosystem; Acute myeloid leukemia, organism-specific biosystem; Acute myeloid leukemia, conserved biosystem; Adaptive Immune System, organism-specific biosystem; Adipocytokine signaling pathway, organism-specific biosystem; Adipocytokine signaling pathway, conserved biosystem; Alpha6-Beta4 Integrin Signaling Pathway, organism-specific biosystem
• Function: ATP binding; RNA polymerase III type 1 promoter DNA binding; RNA polymerase III type 2 promoter DNA binding; RNA polymerase III type 3 promoter DNA binding; TFIIIC-class transcription factor binding; kinase activity; kinase activity; nucleotide binding; phosphoprotein binding; phosphotransferase activity, alcohol group as acceptor; protein binding; protein domain specific binding; protein serine/threonine kinase activity; protein serine/threonine kinase activity; ribosome binding

Reviews

12/27/2020

With its reliable performance and consistent results, the MTOR protein provides researchers with the confidence and accuracy required for successful experimentation.

02/16/2019

The MTOR protein stands out as a protein of exceptional quality, perfectly suited to meet the experimental needs of researchers.

12/01/2016

One remarkable aspect of working with the MTOR protein is the excellent technical support provided by its manufacturer.

Q&As

How does dysregulation of the MTOR pathway contribute to the development of certain diseases?

Dysregulation of the MTOR pathway has been linked to various diseases, including cancer, metabolic disorders, and neurological conditions.

How does the MTOR pathway influence the response to immunotherapy in cancer treatment?

Activation of the MTOR pathway can impair the response to immunotherapy by promoting immunosuppressive mechanisms within the tumor microenvironment.

What are the mechanisms through which the MTOR pathway contributes to drug resistance in cancer?

The enhancement of drug efflux pumps, increased repair of DNA damage, and the promotion of cancer stem cell survival are some of the mechanisms by which the MTOR pathway contributes to drug resistance.

How can the knowledge of the MTOR pathway be leveraged to develop novel cancer therapies?

Understanding the molecular mechanisms of the MTOR pathway can aid in the development of targeted therapies that specifically inhibit its activity, thereby improving cancer treatment outcomes.

What are the implications of MTOR pathway dysregulation in metabolic disorders?

Dysregulation of the MTOR pathway has been linked to metabolic disorders such as obesity, diabetes, and insulin resistance, highlighting its role in metabolic homeostasis.